If so, you or a loved one may be eligible for a clinical study evaluating the safety and effectiveness of the study drug as a treatment for leukemia and lymphoma.
See if you may qualify
You may be eligible to participate in this study if you:
The purpose of the SENTRY-CD19 study is to evaluate a one-time investigational gene therapy called VNX-101. This treatment is designed to help your immune system recognize and destroy cancer cells with a marker called CD19. It may improve outcomes for people whose leukemia or lymphoma has come back or hasn't responded to other treatments.
Gene therapy is a treatment approach to help treat or potentially cure a disease. The study drug being tested in this clinical study is VNX-101, an investigational gene therapy.
This gene therapy works by delivering genetic instructions to the liver, prompting it to produce a protein called GP101. This protein helps the immune system identify and destroy cancer cells with a marker called CD19. The therapy is administered as a single IV (intravenous) infusion, aiming to provide a sustained immune response against cancer.
VNX-101 combines the best attributes of CAR-T therapy and blinatumomab (current standard-of-care therapies) into one product, as an off-the-shelf, single-dose therapy with a long-lasting effect.
By enrolling in this study, you may receive:
This questionnaire will ask for your contact information and a few questions about your medical history to determine your pre-qualification. Then, select a time for a short phone call with PatientWing. PatientWing is partnering with Vironexis (study sponsor) to help identify potential individuals who may be interested in the SENTRY-CD19 study. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
You will have a short call with PatientWing to answer additional questions about your medical history and determine whether you may be potentially eligible. If appropriate, PatientWing will help collect your medical records.
If you are potentially eligible after your conversation with PatientWing, you may meet the research team at the nearest study site, who will review your medical records. If the research team thinks you are a good fit, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question so please share your concerns with the team!
After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:
Click here to fill out the pre-screen questionnaire and express interest in the study. You can also email studies@patientwing.com or call 213-459-2979.
There is no cost to participate in this clinical study. The study sponsor will pay for the costs of the study drug and any study-required tests or procedures. You may discuss travel arrangements and expense-related reimbursements with the research site staff.
You’re free to withdraw from the study at any time before receiving the study drug, as study participation is completely voluntary. Withdrawal will not be used against you nor affect your standard medical care in any way. However, the investigational medication is a single infusion, therefore, once administration is complete, it is not possible to reverse it. The safety visits are an important part of monitoring your health after receiving the investigational medication, but if you wish to withdraw after the infusion has started, you should discuss this with your study doctor. Please contact the study doctor so that they can safely withdraw your participation in the study.
This study lasts for a total of 15 years. It includes approximately 28 visits to your study site for the first 5 years. Each visit will take approximately 1-2 hours. Then, from years 6 to 15, you’ll have yearly phone call follow-ups, unless your study doctor requests an in-person visit.
No, this is an open-label study, so you will not receive a placebo. If you are eligible and choose to enroll, you will receive the study drug, VNX-101.
An answer you provided was outside the guidelines for participating in this study. This does not mean you will not qualify for other or future research studies. Depending on the reason you didn’t qualify, you may have another opportunity to be considered for the study.
Vironexis Biotherapeutics is working to change the way cancer is treated by developing a new kind of gene therapy that helps the immune system fight cancer. Their approach uses gene therapy to deliver treatment with just one dose — no need for complex or repeated procedures. This new method is designed to be easier, faster, and longer-lasting than many current cancer therapies.
Our mission to bring treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.
